Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...

Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...

The identification of all potential EGFR driver mutations is especially critical for patients with lung adenocarcinoma from East Asia or of Asian descent because of the prevalence of such mutations ...

In a recent study published in the journal Nature Biotechnology, researchers in Switzerland used base and prime editing to create and analyze a wide array of variants of the epithelial growth factor ...

When you’re diagnosed with lung cancer, your doctor will classify it as one of two types: small cell lung cancer or non-small-cell lung cancer (NSCLC). NSCLC is far more common. About 85% of all lung ...

Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.

The FDA has accepted a new drug application (NDA) for zipalertinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). If approved, it would be ...